AIMS: Rituximab is approved in rheumatoid arthritis (RA). A substantial decrease in CD4+ count was observed in responders after a single cycle of treatment. This study aimed to describe and quantifying the influence of CD4+ count depletion on the concentration-response relationship of rituximab in RA patients. METHODS: In this retrospective monocentric observational study, 52 patients were assessed. Repeated measurements of rituximab concentrations (pharmacokinetics), CD4+ counts (biomarker) and disease activity score in 28 joints (DAS28, clinical response) were made. Rituximab pharmacokinetics was described using a 2-compartment model, and CD4+ cell counts and DAS28 measurements were described using indirect turnover and direct Emax pharmacokinetic-pharmacodynamic models, respectively. Delay between rituximab concentrations and responses was accounted for by including biophase compartments. RESULTS: Elimination half-life of rituximab was 18 days. The pharmacokinetic-pharmacodynamic model showed that DAS28 response to rituximab was partly associated with CD4+ cell depletion. At 6 months, a deeper DAS28 decrease was observed in patients when CD4+ cell count is decreased: median [interquartile range] of DAS28 was 3.7 [2.9-4.4] and 4.5 [3.7-5.3] in patients with and without CD4+ decrease, respectively. CONCLUSIONS: This is the first study to quantify the relationship between rituximab concentrations, CD4+ count and DAS28 in RA patients. This model showed that approximately 75% of patients had CD4+ count decrease, and that the clinical improvement is 2-fold higher in patients with CD4+ cells decrease than in others.
AIMS: Rituximab is approved in rheumatoid arthritis (RA). A substantial decrease in CD4+ count was observed in responders after a single cycle of treatment. This study aimed to describe and quantifying the influence of CD4+ count depletion on the concentration-response relationship of rituximab in RApatients. METHODS: In this retrospective monocentric observational study, 52 patients were assessed. Repeated measurements of rituximab concentrations (pharmacokinetics), CD4+ counts (biomarker) and disease activity score in 28 joints (DAS28, clinical response) were made. Rituximab pharmacokinetics was described using a 2-compartment model, and CD4+ cell counts and DAS28 measurements were described using indirect turnover and direct Emax pharmacokinetic-pharmacodynamic models, respectively. Delay between rituximab concentrations and responses was accounted for by including biophase compartments. RESULTS: Elimination half-life of rituximab was 18 days. The pharmacokinetic-pharmacodynamic model showed that DAS28 response to rituximab was partly associated with CD4+ cell depletion. At 6 months, a deeper DAS28 decrease was observed in patients when CD4+ cell count is decreased: median [interquartile range] of DAS28 was 3.7 [2.9-4.4] and 4.5 [3.7-5.3] in patients with and without CD4+ decrease, respectively. CONCLUSIONS: This is the first study to quantify the relationship between rituximab concentrations, CD4+ count and DAS28 in RApatients. This model showed that approximately 75% of patients had CD4+ count decrease, and that the clinical improvement is 2-fold higher in patients with CD4+ cells decrease than in others.
Authors: Juan J Perez-Ruixo; Hui C Kimko; Andrew T Chow; Vladimir Piotrovsky; Wojciech Krzyzanski; William J Jusko Journal: J Pharmacokinet Pharmacodyn Date: 2005-12 Impact factor: 2.745
Authors: Thao Pham; Bruno Fautrel; Jacques-Eric Gottenberg; Philippe Goupille; Eric Hachulla; Charles Masson; Jacques Morel; Luc Mouthon; Alain Saraux; Thierry Schaeverbeke; Daniel Wendling; Xavier Mariette Journal: Joint Bone Spine Date: 2008-06 Impact factor: 4.929
Authors: Javier Narvaez; Cesar Díaz-Torné; Jose Miguel Ruiz; Maria Victoria Hernandez; Vicente Torrente-Segarra; Sergio Ros; Arturo Rodriguez de la Serna; Cesar Díaz-López; Raimon Sanmartí; Joan Miquel Nolla Journal: Clin Exp Rheumatol Date: 2011-12-22 Impact factor: 4.473
Authors: M Hellerstein; M B Hanley; D Cesar; S Siler; C Papageorgopoulos; E Wieder; D Schmidt; R Hoh; R Neese; D Macallan; S Deeks; J M McCune Journal: Nat Med Date: 1999-01 Impact factor: 53.440
Authors: Adeline Ruyssen-Witrand; Stéphanie Rouanet; Bernard Combe; Maxime Dougados; Xavier Le Loët; Jean Sibilia; Jacques Tebib; Xavier Mariette; Arnaud Constantin Journal: Rheumatology (Oxford) Date: 2012-12-22 Impact factor: 7.580
Authors: Giancarlo Comi; Amit Bar-Or; Hans Lassmann; Antonio Uccelli; Hans-Peter Hartung; Xavier Montalban; Per Solberg Sørensen; Reinhard Hohlfeld; Stephen L Hauser Journal: Ann Neurol Date: 2020-11-04 Impact factor: 10.422